Leading the Way in Life Science Technologies

GEN Exclusives

More »

Insight & Intelligence™

Back to Item »

With Oligonucleotide Drugs, Antisense Arrives but RNAi Has a Long Way to Go

Isis filed an NDA for its HoFH antisense treatment, while Alnylam reported Phase III failure with RSV infection RNAi candidate.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »